ProPhase Labs Q4 2022 Earnings Report $0.63 0.00 (-0.62%) (As of 05:36 PM ET) Earnings HistoryForecast ProPhase Labs EPS ResultsActual EPS-$0.08Consensus EPS $0.02Beat/MissMissed by -$0.10One Year Ago EPSN/AProPhase Labs Revenue ResultsActual Revenue$21.82 millionExpected Revenue$20.53 millionBeat/MissBeat by +$1.29 millionYoY Revenue GrowthN/AProPhase Labs Announcement DetailsQuarterQ4 2022Date3/28/2023TimeN/AConference Call ResourcesPress ReleasePRPH Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.” (Ad)In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation. Now, Jeff has found five under-the-radar stocks which could power your retirement. ProPhase Labs Earnings HeadlinesProPhase Labs finalizing set of cost-saving measures for non-core operationsDecember 12, 2024 | markets.businessinsider.comProPhase Labs secures private equity backing, nears lozenge dealDecember 12, 2024 | markets.businessinsider.comMan Who Called Nvidia Says: “Your Retirement Is Inside This Building.”In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation.December 26, 2024 | Brownstone Research (Ad)ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comProPhase Labs: Strategic Moves for Future GrowthNovember 14, 2024 | markets.businessinsider.comSee More ProPhase Labs Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProPhase Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProPhase Labs and other key companies, straight to your email. Email Address About ProPhase LabsProPhase Labs (NASDAQ:PRPH) develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.View ProPhase Labs ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
